{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(3)"],"submitter":["Jung J"],"pubmed_abstract":["<h4>Background</h4>Second salvage autologous stem cell transplantation (SAT) is a therapeutic option for patients with multiple myeloma (MM) who relapse after a first autologous stem cell transplantation (ASCT) in the era of novel agents. However, the clinical context in which SAT provides benefit relative to contemporary salvage regimens remains unclear.<h4>Methods</h4>We retrospectively analyzed 51 patients who underwent SAT after novel agent-based induction and first ASCT, and salvage re-induction, and compared outcomes with 113 patients treated with salvage carfilzomib-lenalidomide-dexamethasone (KRd) without SAT.<h4>Results</h4>Median interval from first ASCT to relapse was 27 months. In the SAT cohort, median progression-free survival (PFS) and overall survival (OS) from initiation o"],"journal":["Cancers"],"pagination":["471"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12896849"],"repository":["biostudies-literature"],"pubmed_title":["Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study."],"pmcid":["PMC12896849"],"pubmed_authors":["Jung SH","Jung J","Park JH","Eom HS","Kang HJ","Korean Multiple Myeloma Working Party (KMMWP)","Kim K","Min CK","Yoo KH","Byun JM","Yoon DH","Lee MW","Jo JC","Kim SH","Cho H","Yi JH","Lee JJ","Lee SS","Yoon SE","Lee WS","Lee JH","Do YR","Shin HJ"],"additional_accession":[]},"is_claimable":false,"name":"Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study.","description":"<h4>Background</h4>Second salvage autologous stem cell transplantation (SAT) is a therapeutic option for patients with multiple myeloma (MM) who relapse after a first autologous stem cell transplantation (ASCT) in the era of novel agents. However, the clinical context in which SAT provides benefit relative to contemporary salvage regimens remains unclear.<h4>Methods</h4>We retrospectively analyzed 51 patients who underwent SAT after novel agent-based induction and first ASCT, and salvage re-induction, and compared outcomes with 113 patients treated with salvage carfilzomib-lenalidomide-dexamethasone (KRd) without SAT.<h4>Results</h4>Median interval from first ASCT to relapse was 27 months. In the SAT cohort, median progression-free survival (PFS) and overall survival (OS) from initiation o","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-08T03:14:00.26Z","creation":"2026-07-08T03:08:34.542Z"},"accession":"S-EPMC12896849","cross_references":{"pubmed":["41681943"],"doi":["10.3390/cancers18030471"]}}